Back HIV/AIDS HIV/AIDS Topics HIV Treatment

Gilead and Janssen Announce Deal to Develop New TAF Single-Tablet Regimens

Gilead Sciences and Janssen R&D announced an agreement in late December to develop antiretroviral coformulations containing Gilead's novel tenofovir alafenamide (TAF) formulation and emtricitabine plus Janssen's HIV protease inhibitor darunavir (Prezista) or NNRTI rilpivirine (Edurant).

alt

Read more:

Top 14 HIV and Hepatitis Stories of 2014

2014 was an exciting year in the fields of HIV and viral hepatitis, highlighted by growing awareness and promising new data for HIV pre-exposure prophylaxis (PrEP) and approval of highly effective new interferon-free combination pills for hepatitis C. But there were also some setbacks and challenges, including disappointments in HIV cure research and the high cost of the new hepatitis C drugs.

alt

Read more:

8. HIV Treatment Cascade: Majority in U.S. Have Uncontrolled Virus

On the HIV treatment cascade front, the Centers for Disease Control and Prevention reported in December that less than one-third of people living with HIV in the U.S. have an undetectable viral load, with most of the drop-off attributable to people who had been diagnosed with HIV but did not go on to receive further care

alt

Read more:

4. HIV Cure Setbacks: Mississippi Baby and Bone Marrow Transplants

The quest for an HIV cure saw some setbacks in 2014, with further news about 2 stem cell transplant patients in Boston who experienced HIV rebound several months after interrupting antiretroviral therapy (ART). This was followed in July by an announcement that HIV was detected in a child in Mississippi who had maintained undetectable viral load for more than 2 years off treatment.

alt

Read more:

CCR5-Delta-32 Stem Cell Transplants Unsuccessful in 6 Patients -- Berlin Patient Remains the Sole HIV Cure

Bone marrow transplants from donors with a naturally occurring mutation that protects immune cells from HIV failed to cure 6 additional HIV positive blood cancer patients, leaving "Berlin Patient" Timothy Ray Brown as the only person to show no signs of HIV infection several years after receiving this type of transplant, Brown's doctor Gero Hütter reported in the December 18 New England Journal of Medicine. Brown recently published his own story of being the only man known to be cured of HIV.alt

Read more:

6. HIV Drugs: Few New Approvals, but Pipeline Looks Promising

HIV drug development news in 2014 included approval of a new single-tablet regimen and 2 more components of antiretroviral therapy (ART). Promising candidates in the pipeline include a better-tolerated version of tenofovir, a NNRTI with fewer neuropsychiatric side effects, and potential long-acting injectables that may be useful for treatment or pre-exposure prophylaxis.

alt

Read more:

HIVandHepatitis.com 2014 Conference Coverage

Links to full listing of on-site conference coverage during 2014.

alt

Read more: